breast cancer

FDA expands off-label use of Herceptin breast cancer drug

Friday, November 17, 2006 by: Jessica Fraser
Tags: herceptin, breast cancer, off-label prescribing

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
BACK INTO THE CLOSET: Why U.S. reporters are not allowed to write about rainbow events in nations where being gay is still condemned
Depopulation test run? 75% of children who received vaccines in Mexican town now dead or hospitalized
A family destroyed: Six-month-old dies after clinic injects baby with 13 vaccines at once without mother's informed consent
Biologist explains how marijuana causes tumor cells to commit suicide
INVESTIGATION: Three days before Dr. Bradstreet was found dead in a river, U.S. govt. agents raided his research facility to seize a breakthrough cancer treatment called GcMAF
BOMBSHELL: China and America already at war: Tianjin explosion carried out by Pentagon space weapon in retaliation for Yuan currency devaluation... Military helicopters now patrolling Beijing
Companies begin planting microchips under employees' skin
BAM! Chipotle goes 100% non-GMO; flatly rejecting the biotech industry and its toxic food ingredients
ECONOMIC SLAVERY FOR ALL: While we were distracted with the Confederate flag flap, Congress quietly forfeited our entire economic future via fast-track trade authority
NJ cops bust teenagers shoveling snow without a permit
McDonald's in global profit free fall as people everywhere increasingly reject chemically-altered toxic fast food
March Against Monsanto explodes globally... World citizens stage massive protests across 38 countries, 428 cities... mainstream media pretends it never happened
Italian court rules mercury and aluminum in vaccines cause autism: US media continues total blackout of medical truth
SCOTUS same-sex marriage decision may have just legalized the concealed carry of loaded firearms across all 50 states, nullifying gun laws everywhere
Orthorexia Nervosa - New mental disorder aimed at people who insist on eating a clean diet
Vicious attack on Dr. Oz actually waged by biotech mafia; plot to destroy Oz launched after episode on glyphosate toxicity went viral
Nearly every mass shooting in the last 20 years shares one surprising thing? and it's not guns
Holistic cancer treatment pioneer Dr. Nicholas Gonzalez dies suddenly; patients mourn the loss of a compassionate, innovative doctor who helped thousands heal from cancer
Delicious
(NaturalNews) The U.S. Food and Drug Administration announced yesterday that it has formally agreed to expand the off-label use of Genentech's Herceptin breast cancer drug to include patients with early-stage breast cancer who have undergone surgery.

The FDA's decision to expand Herceptin prescribing practices was expected in August, but the agency requested more information prior to its decision. However, according to Citigroup analysts, doctors across the country were already extensively prescribing Herceptin to early-stage breast cancer patients before the FDA gave approval.

Herceptin first entered the market in 1998 as a treatment for the 25 to 30 percent of breast cancer patients whose tumors generate a protein called HER-2. The drug was recommended for patients whose cancer had spread beyond the breast.

After Genentech announced last year that it had conducted a trial yielding positive results for the use of Herceptin in combination with chemotherapy in early-stage cancer patients, doctors began writing off-label prescriptions for the drug in such patients, prior to FDA approval.

Off-label prescribing is the practice of a physician prescribing a drug to treat a condition for which the FDA has not approved the drug. Essentially, once a drug is approved to treat one condition, it can then be legally prescribed to treat any other condition, despite lack of safety or effectiveness testing for treating unapproved conditions.

In the first nine months of 2006, U.S. sales of Herceptin increased by 84 percent from the same period in 2005, to $912 million. Citigroup says the FDA's approval of off-label prescriptions is unlikely to increase sales further, since doctors had already been prescribing the drug for early-stage patients.

Consumer health advocate Mike Adams, author of a critical cartoon on Herceptin, said, "The FDA's wink-and-nod tolerance of off-label prescribing makes a mockery of the entire drug approval process.

"Today's laws say that doctors can prescribe any drug for literally any condition, regardless of whether it has ever been approved or even tested for such conditions," he said. "To call this 'evidence-based medicine' is downright laughable."

A study appearing in the August issue of the Journal of Clinical Oncology found that Herceptin caused heart damage in 28 percent of its users.

###

Follow real-time breaking news headlines on
Herceptin at FETCH.news
Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.